Sublingual Immunotherapy for Allergic Rhinitis and Conjunctivitis

Giovanni Passalacqua; Valentina Garelli; Francesca Sclifò; Giorgio Walter Canonica


Immunotherapy. 2013;5(3):257-264. 

In This Article


Allergic rhinitis is a major public health concern with significant healthcare costs, also representing an independent risk factor for the development of asthma. SLIT has been consistently shown to be capable of reducing symptoms and medication use in allergic rhinitis and possibly in coexistent asthma[70] for all the relevant allergens. In addition, due to the complex mechanism of action, SLIT profoundly modifies the immune response, thus, its effects last for many years.[71] Finally, SLIT, as well as SCIT, can reduce the risk of asthma onset in children with allergic rhinitis. According to this evidence, SLIT is confirmed to be a viable alternative to SCIT in the treatment of allergic rhinoconjunctivitis, with a very favorable safety profile and the possibility of expanding the indications to other diseases.